In contrast, the phase III ADMIRAL trial, which randomized relapsed/refractory FLT3-mutated AML patients to gilteritinib or chemotherapy salvage, demonstrated a dramatically improved response rate among gilteritinib-treated patients who had previously undergone allo-HCT (36% vs. 18% for non-transplant patients) and improved survival among post-transplant patients randomized to gilteritinib versus chemotherapy (73). Here, FLT3 is linked to acute myeloid leukemia.